High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma

BMC Cancer

Xuelian Cui²  Lianhua Li³  Guanghai Yan²  Kai Meng²  Zhenhua Lin²  Yunze Nan³  Guang Jin¹  Chunyu Li² 

[1] Department of Pathology, Yanbian University Medical College, Yanji 133002, China

[2] Cancer Research Center, Yanbian University, Yanji 133002, China

[3] Department of Gynecology & Obstetrics, Yanbian University Hospital, Yanji 133000, China

关键词: Survival analysis;    Immunohistochemistry;    NQO1;    Ovarian carcinoma;   

Others  :  1171812
DOI  :  10.1186/s12885-015-1271-4

 received in 2014-07-30, accepted in 2015-03-26,  发布年份 2015

【 摘 要 】

Background

NAD(P)H:quinone oxidoreductase (NQO1) is a flavoprotein that catalyzes two-electron reduction and detoxification of quinones and its derivatives. NQO1 catalyzes reactions that have a protective effect against redox cycling, oxidative stress and neoplasia. High expression of NQO1 is associated with many solid tumors including those affecting the colon, breast and pancreas; however, its role in the progression of ovarian carcinoma is largely undefined. This study aimed to investigate the clinicopathological significance of high NQO1 expression in serous ovarian carcinoma.

Methods

NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect NQO1 mRNA expression levels. The correlation between high NQO1 expression and clinicopathological features of ovarian carcinoma was evaluated by Chi-square and Fisher’s exact test. Overall survival (OS) rates of all of ovarian carcinoma patients were calculated using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional hazards regression model.

Results

NQO1 protein expression in ovarian carcinoma cells was predominantly cytoplasmic. Strong, positive expression of NQO1 protein was observed in 63.8% (102/160) of ovarian carcinomas, which was significantly higher than in borderline serous tumors (32.3%, 20/62) or benign serous tumors (11.3%, 6/53). Importantly, the rate of strong, positive NQO1 expression in borderline serous tumors was also higher than in benign serous tumors. High expression of NQO1 protein was closely associated with higher histological grade, advanced clinical stage and lower OS rates in ovarian carcinomas. Moreover, multivariate analysis indicated that NQO1 was a significant independent prognostic factor, in addition to clinical stage, in patients with ovarian carcinoma.

Conclusions

NQO1 is frequently upregulated in ovarian carcinoma. High expressin of NQO1 protein may be an effective biomarker for poor prognostic evaluation of patients with serous ovarian carcinomas.

【 授权许可】

   
2015 Cui et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2012, 62(1):10-29.
• [2]Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J: Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci 2013, 14:9536-55.
• [3]Marsden DE, Friedlander M, Hacker NF: Current management of epithelial ovarian carcinoma. Semin Surg Oncol 2000, 19:11-9.
• [4]Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D: NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000, 129:77-97.
• [5]Siegel D, Yan C, Ross D: NAD (P) H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012, 83(8):1033-40.
• [6]Nioi P, Hayes JD: Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 2004, 555:149-71.
• [7]Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V: Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol 2009, 135:515-22.
• [8]Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H: Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002, 21:1119-24.
• [9]Cresteil T, Jaiswal AK: High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origan. Biochem Pharmacol 1991, 42:1021-7.
• [10]Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT: DTdiaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev 1993, 12:83-101.
• [11]Tedeschi G, Chen S, Massey V: DT-diaphorase. Redox potential, steadystate, and rapid reaction studies. J Biol Chem 1995, 270:1198-204.
• [12]Smitskamp-Wilms E, Hendriks HR, Peters GJ: Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Gen Pharmacol 1996, 27:421-9.
• [13]Ross D, Beall H, Traver RD, Siegel D, Phillips RM: Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 1994, 6:493-500.
• [14]Cadenas E: Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995, 49:127-40.
• [15]Ross D, Siegel D: NAD(P)H:quinone oxidoreductase 1 (NQO1, DTdiaphorase), functions and pharmacogenetics. Methods Enzymol 2004, 382:115-44.
• [16]Ma Y, Kong J, Yan G, Ren S, Jin D, Jin T, et al.: NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer 2014, 14:414. BioMed Central Full Text
• [17]Siegel D, Franklin WA, Ross D: Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998, 4(9):2065-70.
• [18]Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, et al.: NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 2008, 16(1):24-31.
• [19]Garate M, Wani AA, Li G: The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 2010, 48(12):1601-9.
• [20]Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, et al.: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 2013, 13:366. BioMed Central Full Text
• [21]Ernster L, Navazio F: Soluble diaphorase in animal tissues. Acta Chem Scand 1958, 12:595-602.
• [22]Winski SL, Koutalos Y, Bentley DL, Ross D: Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res 2002, 62:1420-4.
• [23]Lee H, Oh ET, Choi BH, Park MT, Lee JK, Lee JS, et al.: NQO1-induced activation of AMPK contributes to cancer cell death by oxygen-glucose deprivation. Sci Rep 2015, 5:7769.
• [24]Girolami F, Abbadessa G, Racca S, Spaccamiglio A, Piccione F, Dacasto M, et al.: Time-dependent acetylsalicylic acid effects on liver CYP1A and antioxidant enzymes in a rat model of 7,12-dimethylbenzanthracene(DMBA)-induced mammary carcinogenesis. Toxicol Lett 2008, 181:87-92.
• [25]Iskander K, Gaikwad A, Paquet M, Long DJ II, Brayton C, Barrios R, et al.: Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res 2005, 65:2054-8.
• [26]Long DJ, Waikel RL, Wang XJ, Roop DR, Jaiswal AK: NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst 2001, 93:1166-70.
• [27]Choi TY, Sohn KC, Kim JH, Kim SM, Kim CH, Hwang JS, et al.: Impact of NAD(P)H:quinone oxidoreductase-1 on pigmentation. J Invest Dermatol 2010, 130(3):784-92.
• [28]Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D: Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry 2007, 46:5941-50.
• [29]Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K, et al.: C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin. Clin Med Insights Oncol 2013, 7:31-9.
• [30]Malik MA, Zargar SA, Mittal B: Role of NQO1 609C > T and NQO2–3423G > A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis. Mol Biol Rep 2012, 39(9):9095-104.
• [31]Lin L, Qin Y, Jin T, Liu S, Zhang S, Shen X, et al.: Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Exp Mol Pathol 2014, 96(2):200-5.
• [32]Goode EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, Schildkraut JM, et al.: Xenobiotic-metabolizing gene polymorphisms and Ovarian cancer risk. Mol Carcinog 2011, 50(5):397-402.
• [33]Siegel D, Ross D: Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000, 29:246-53.
• [34]Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, et al.: Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res 2014, 33:14. BioMed Central Full Text
• [35]Buranrat B, Chau-In S, Prawan A, Puapairoj A, Zeekpudsa P, Kukongviriyapan V: NQO1 Expression correlates with cholangiocarcinoma prognosis. Asian Pac J Cancer Prev 2012, 13(Suppl):131-6.
• [36]Workman P: Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 1994, 6:461-75.
• [37]Kung H, Weng T, Liu Y, Lu K, Chau Y: Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells. PLoS One 2014, 9(2):e88122.
• [38]Hadley K, Hendricks D: Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. BMC Cancer 2014, 14:334. BioMed Central Full Text
• [39]Huang X, Dong Y, Bey E: An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 2012, 72:3038-47.